GlassScriptPhysician profile
Mark Andrew Kissinger
NPI 1992760474
$3,842.96
in general payments reported to CMS, 2019-2025
27 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $76.19 · 2021: $54.40 · 2022: $314 · 2023: $628 · 2024: $974 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $668.64 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $560.66 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $497.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $342.31 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $224.49 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.51 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $182.17 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $159.59 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbvie INC. | $143.91 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $129.26 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $111.56 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $108.94 | 2023-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $78.24 | 2025 | Zoryve |
| Abbott Laboratories | $77.92 | 2019-2024 | Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $53.04 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $48.79 | 2024 | Edarbi, Horizant |
| Astellas Pharma US INC | $37.18 | 2023-2024 | Veozah |
| Shield Therapeutics INC | $34.83 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $34.27 | 2019 | |
| Acella Pharmaceuticals, LLC | $33.45 | 2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $30.35 | 2025 | |
| Sumitomo Pharma America, INC. | $20.99 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $20.93 | 2022 | |
| Esperion Therapeutics, INC. | $15.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.21 | 2022 | |
| Currax Pharmaceuticals LLC | $13.90 | 2023 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kissinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.